Early attempts at the reinduction of 131I uptake by redifferentiation of 131I-negative differentiated thyroid cancer (DTC) had limited success. Novel therapies targeting the pathways that restore expression of the sodium iodine symporter now offer new hope of success for redifferentiation therapy in DTCs with the BRAFV600E mutation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Winter, J. et al. Patients with high-risk differentiated thyroid cancer have a lower I-131 ablation success rate than low-risk ones in spite of a high ablation activity. Clin. Endocrinol. (Oxf.) http://dx.doi.org/10.1111/cen.13123 (2016).
Verburg, F. A. et al. Life expectancy is reduced in differentiated thyroid cancer patients ≥ 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients. J. Clin. Endocrinol. Metab. 98, 172–180 (2013).
Nagarajah, J. et al. Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine. J Clin. Invest. http://dx.doi.org/10.1172/JCI89067 (2016).
Simon, D. et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur. J. Nucl. Med. Mol. Imag. 29, 775–782 (2002).
Tepmongkol, S., Keelawat, S., Honsawek, S. & Ruangvejvorachai, P. Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-γ. Thyroid 18, 697–704 (2008).
Hoftijzer, H. et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur. J. Endocrinol. 161, 923–931 (2009).
Ho, A. L. et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N. Engl. J. Med. 368, 623–632 (2013).
Ho, A. L. et al. The ASTRA study: adjuvant selumetinib for differentiated thyroid cancer (DTC); remission after radioiodine. http://thyroidworldcongress.com/wp-content/uploads/2013/07/P102_Ho.pdf (2013).
Brose, M. S. et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384, 319–328 (2014).
Schlumberger, M. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372, 621–630 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
F.A.V. has been a consultant for Bayer Healthcare and Sanofi Genzyme and received speaker honoraria from Diasorin and Sanofi Genzyme. M.L. has been a consultant for AstraZeneca, Bayer Healthcare, Sanofi Genzyme and Sobi and received speaker honoraria and research support from Henning, Sanofi Genzyme and Merck.
Rights and permissions
About this article
Cite this article
Verburg, F., Luster, M. Redifferentiation — a 'new' option for 131I-negative DTC. Nat Rev Endocrinol 13, 9–10 (2017). https://doi.org/10.1038/nrendo.2016.182
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2016.182
